Study: Early Mesothelioma HIPEC Surgery Extends Survival
Sooner is better when it comes to aggressively treating peritoneal mesothelioma cancer with a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Waiting could cost a patient months of survival. Rejecting surgery could cost them years. The Journal of Gastrointestinal Surgery published a study in November that showed for the first time to what degree a delay in having the mesothelioma surgery, or not getting it at all, can affect overall survival for patients. Results of the mesothelioma study were presented earlier this year at the annual Society for Surgery of the Alimentary Tract meeting in San Diego. Surgeons and oncologists from Abramson Cancer Center at the University of Pennsylvania, Sidney Kimmel Medical College in Philadelphia and the University of Colorado Hospital in Aurora co-authored the study. “These findings reinforce the important role timely surgery can play in patients with peritoneal mesothelioma,” surgical oncologist and co-author Dr. Giorgos Karakousis, of Abramson Cancer Center, told The Mesothelioma Center at Asbestos.com. Mesothelioma Life Expectancy Rises With Surgery Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as CRS-HIPEC, has become an effective treatment of choice for mesothelioma specialists in recent years. This latest life expectancy simulator looked at 1,000 cases of peritoneal mesothelioma in three different categories: timely treatment (fewer tha...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Fran Mannino Tags: Peritoneal Surgical procedures Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Education | Environmental Health | Gastroenterology | Hospitals | Mesothelioma | Pain | Pain Management | Palliative | Palliative Care | Study | Toxicology | University of Pennsylvania